Every day, articles older than 90 days are removed from the main list and are kept here, organized by topic, with only the title and link to the source. The search and the MielomaAI You may find them too.
Pay attention to old news. Marked as. about 1 year 2 years 5 years 10 years You may also want to check that the information is still up to date: treatments, approvals and prices change quickly. Always confirm with your hematology team.
Research
- The specific combination of J&J reduces the risk of myeloma progression by 89% in a Phase 3 study. ↗ · Fierce Pharma · 23/07/2026
- The TECVAYLI® + TALVEY® combination reduced the risk of disease progression or death by 89% and the risk of death by 62% in patients with relapsed/refractory multiple myeloma in the first-line setting. · PR Newswire · 07/23/2026
- Bispecific Antibody FcRH5xCD3 cevostamab in recurrent or refractory multiple myeloma: a Phase 1 trial ↗ · Nature · 22/07/2026
- Research to help people with multiple myeloma live longer. · Canadian Institutes of Health Research · 13/07/2026
- Research that helps people live longer with multiple myeloma. · Canadian Institutes of Health Research · 13/07/2026
- Multiple myeloma, the Nantes University Hospital is at the heart of clinical research to advance treatments. ↗ · CHU Media · 08/06/2026
- Significant advances on the front lines and the potential of MRD negativity in multiple myeloma ↗ · My Hematology — search "multiple myeloma" (page 3) · 26/05/2026
- The future of multiple myeloma ↗ · Observer · 22/04/2026
- First results from the first in vivo CAR-T study in multiple myeloma ↗ · The ASCO Post · February 25, 2026
- New drug for multiple myeloma shows promise in early study. ↗ · Open Access Government · 23/02/2026
- Pioneering drug candidate shows promise in Phase 1 myeloma study. · Imperial College London · February 23, 2026
- Regeneron: drug eliminates myeloma cells in a small trial ↗ · Reuters · 10/12/2025
- ASH: anita-cel strengthens the potential to be the best in class while Kite, from Gilead, prepares the launch. · Fierce Biotech · 12/07/2025
- Phase 1 trial of the CAR-T BCMA NEX-T® CC-98633/BMS-986354 therapy in patients with multiple myeloma who have been previously exposed to three classes of drugs ↗ about 1 year · Nature · 05/02/2025
- Phase 2 registration study of anitocabtagene autoleucel in multiple myeloma relapsed and/or refractory: preliminary results from the iMMagine-1 trial ↗ about 1 year · International Myeloma Society · January 30, 2025
- Phase 3 study of teclistamab with lenalidomide, and teclistamab alone, versus lenalidomide in maintenance after autotransplant in newly diagnosed multiple myeloma: preliminary safety results from the MajesTEC-4/EMN30 trial ↗ about 1 year · International Myeloma Society · January 30, 2025
- Phase 2 study of inductions with teclistamab in patients newly diagnosed with transplant eligibility: results of the GMMG-HD10/DSMM-XX (MajesTEC-5) trial ↗ about 1 year · International Myeloma Society · January 30, 2025
- First results from the Phase 1 study, the first in humans, with ISB 2001, a triespecific BCMA×CD38×CD3 antibody, in relapsed/refractory multiple myeloma ↗ about 1 year · International Myeloma Society · January 30, 2025
- A new breakthrough in the treatment of multiple myeloma: the promising results of the BENEFIT study. about 1 year · University Hospital of Poitiers Website · 24/01/2025
- ASH 2024: Multiple Myeloma Studies May Change Practice about 1 year · Hematology Advisor · 18/12/2024
- Indapta Therapeutics announces collaboration with Sanofi in a clinical trial for multiple myeloma ↗ about 1 year · Business Wire · 06/12/2024
- Multiple myeloma: cilta-cel proved to be highly effective in a study in real-world clinical practice ↗ 2 years · ScienceDaily — Multiple Myeloma · 10/04/2024
- Efficacy and safety of Isa-KRd induction prior to adapted consolidation based on response in newly diagnosed multiple myeloma with indication for transplant: interim analysis of the IFM2020-02 MIDAS study ↗ 2 years · International Myeloma Society · 27/09/2024
- Blood proteins predict the risk of over 60 diseases ↗ 2 years · ScienceDaily — Multiple Myeloma · 22/07/2024
- Modified plasmacytoid cells show sustained anti-leukemic activity in mice. 2 years · ScienceDaily — Multiple Myeloma · 02/07/2024
- AbbVie initiates Phase 3 trial for multiple myeloma with the experimental drug ABBV-383 ↗ 2 years · PR Newswire · 05/06/2024
- Obesity linked to the detection of a precursor condition for blood cancer ↗ 2 years · ScienceDaily — Multiple Myeloma · 15/01/2024
- Getting precise about multiple myeloma ↗ 2 years · Cancer Research UK - Cancer News · 08/01/2024
- Arcellx announced strong and durable responses of the CART-ddBCMA (anito-cel) regimen in the Phase 1 trial in patients with multiple myeloma in relapse or refractory status. 2 years · PR Newswire · 08/12/2023
- Women who live in neighborhoods easier to walk around have fewer cancers linked to obesity ↗ 3 years · ScienceDaily — Multiple Myeloma · 10/04/2023
- Sequential therapy study in multiple myeloma relapse ↗ 3 years · SciELO Spain · 25/09/2023
- Elranatamab in relapsed or refractory multiple myeloma: results of the MagnetisMM-3 phase 2 trial 3 years · Nature · August 15, 2023
- Multiple myeloma ↗ 3 years · Cancer Research UK - Cancer News · 20/07/2023
- Tecvayli shows promising results in multiple myeloma ↗ 4 years ago · National Cancer Institute (.gov) · 20/10/2022
- New photon counting TAC detects disease better in myeloma ↗ 4 years ago · ScienceDaily — Multiple Myeloma · 06/09/2022
- GSK presents at the ASH 2021 annual meeting the advances of the DREAMM trial program in multiple myeloma. 4 years ago · GSK · 18/11/2021
- Genetics as prognostic and treatment factor in multiple myeloma ↗ 5 years · Scielo.cl · 26/06/2021
- Research into multiple myeloma at Clínic Hospital 6 years · Clínic Barcelona · 22/12/2019
- GSK announces positive top-line results from the pivotal DREAMM-2 study in multiple myeloma ↗ 7 years · GSK · 23/08/2019
- Multiple myeloma research lines ↗ 7 years · Clínic Barcelona · 29/07/2019
- Research on myeloma ↗ 8 years · Cancer Research UK · 29/06/2018
- Symptoms of myeloma ↗ 8 years · Cancer Research UK · 29/06/2018
- Research and clinical trials for myeloma ↗ 8 years · Cancer Research UK · 29/06/2018
- Multiple myeloma ↗ 8 years · Cancer Research UK · 28/06/2018
- ASH: Johnson & Johnson achieves major win with Darzalex in first-line myeloma and reduces risks by half ↗ 8 years · Fierce Pharma · 12/12/2017
- According to a researcher at the Mayo Clinic: the treatment of multiple myeloma ↗ 9 years · Mayo Clinic News Network · 11/06/2017
- The Multiple Myeloma Research Foundation’s focus on drug research has increased ↗ 14 years · Nature · July 10, 2012
